Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Short term Debt: 2022

Historic Short term Debt for RedHill Biopharma (RDHL) over the last 1 years, with Dec 2022 value amounting to $115.2 million.

  • RedHill Biopharma's Short term Debt was N/A to $115.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $115.2 million, marking a year-over-year change of. This contributed to the annual value of $115.2 million for FY2022, which is N/A change from last year.
  • RedHill Biopharma's Short term Debt amounted to $115.2 million in FY2022.
  • RedHill Biopharma's Short term Debt's 5-year high stood at $115.2 million during FY2022, with a 5-year trough of $115.2 million in FY2022.
  • In the last 1 years, RedHill Biopharma's Short term Debt had a median value of $115.2 million in 2022 and averaged $115.2 million.